| Literature DB >> 23061875 |
Lucie Brosseau1, George A Wells, Glen P Kenny, Robert Reid, Andreas Maetzel, Peter Tugwell, Maria Huijbregts, Carolyn McCullough, Gino De Angelis, Lily Chen.
Abstract
BACKGROUND: The implementation of evidence based clinical practice guidelines on self-management interventions to patients with chronic diseases is a complex process. A multifaceted strategy may offer an effective knowledge translation (KT) intervention to promote knowledge uptake and improve adherence in an effective walking program based on the Ottawa Panel Evidence Based Clinical Practice Guidelines among individuals with moderate osteoarthritis (OA).Entities:
Mesh:
Year: 2012 PMID: 23061875 PMCID: PMC3491047 DOI: 10.1186/1471-2458-12-871
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Knowledge-To-Action Cycle. This figure illustrates the Knowledge-To-Action Cycle Framework [8]. This figure is used with permission: Lost in knowledge translation: Time for a map. Graham ID, et al. Journal of Continuing Education in the Health Professions, 26(1). Copyright © 2006. The Alliance for Continuing Medical Education, The Society for Academic Continuing Medical Education, and The Association for Hospital Medical Education.
Summary of the KT strategies used
| WB or WalkingClub+ (supervised walking program + behavioural approach at the community-based Walking Club) | W or WalkingClub (supervised walking program only at the community-based Walking Club) | C or Self-directed Home-based or community based different than W and WB (unsupervised/self-directed Walking program only) |
| EBP walking program (Ottawa Panel, 2005/2012) refs:
[ | EBP walking program (Ottawa Panel, 2005/2012) refs:
[ | Walking program (general info from pamphlet on walking and OA) |
| Walking Club + effect (supervised program, team, daily monitored vital measures: BP, HR, #steps,) | Walking Club effect (supervised program, team, daily monitored vital measures: BP, HR, #steps,) | N/A |
| Pedometer as measurement tool, but becomes a KT strategy | Pedometer as measurement tool, but becomes a KT strategy | Pedometer as measurement tool, but becomes a KT strategy |
| Log book including 7-day PAR as measurement tool, but becomes a KT strategy | Log book including 7-day PAR as measurement tool, but becomes a KT strategy | Log book including 7-day PAR as measurement tool, but becomes a KT strategy |
| $ compensation each walking session and at evaluation session | $ compensation each walking session and at evaluation session | $ compensation each logbook fulfilled and at evaluation session |
| Study affiliation/participation (feel committed) | Study affiliation/participation (feel committed) | Study affiliation/participation (feel committed) |
| Behavioural intervention (Baycrest PACE-ex: patient education + goal settings; PA counselling, telephone support) | N/A | N/A |
Subject demographics and baseline characteristics
| 63.9 (10.3) | 63.9 (8.2) | 62.3(6.8) | 63.4 (8.6) | |
| 24 (30.4)/55 (69.9) | 18 (26.1)/51 (73.9) | 27 (36.5)/47 (63.5) | 69 (31.1)/153 (68.9) | |
| | | | | |
| Right | 33 (41.8) | 31 (44.9) | 25 (33.8) | 89 (40.1) |
| Left | 31(39.2) | 23 (33.3) | 28 (37.8) | 82 (36.9) |
| Both side | 15 (19.0) | 15 (28.4) | 21 (28.4) | 51 (23.0) |
| 9.54 (8.09) | 11.3 (9.7) | 10.0 (9.9) | 10.3 (9.26) | |
| 80.7 (18.5) | 83.1 (15.4) | 83.0(15.8) | 82.2 (16.6) | |
| 29.4 (5.4) | 30.3 (5.6) | 29.9(5.3) | 29.8 (5.4) | |
| | | | | |
| Yes | 10 (12.7) | 10 (14.5) | 9 (12.2) | 29 (13.1) |
| No | 69 (87.3) | 58 (84.1) | 64 (86.5) | 191 (86.0) |
| | | | | |
| White | 69 (87.3) | 60 (87.0) | 68 (91.9) | 197 (88.7) |
| Black | 1 (1.3) | 3 (4.3) | 1 (1.4) | 5 (2.3) |
| Hispanic | 2 (2.5) | 2 (2.9) | 4 (5.4) | 8 (3.6) |
| Asian or Pacific Islander | 5 (6.3) | 4 (5.8) | 1 (1.4) | 10 (4.5) |
| American Indian or Alaskan native | 1 (1.3) | 0 (0) | 0 (0) | 1 (0.5) |
| Other | 1 (1.3) | 0 (0) | 0 (0) | 1 (0.5) |
| | | | | |
| Married | 46 (58.2) | 36 (52.2) | 44 (59.5) | 126 (56.8) |
| Separated | 2 (2.5) | 1 (1.4) | 1 (1.4) | 4 (1.8) |
| Divorced | 9 (11.4) | 17 (24.6) | 8 (10.8) | 34 (15.3) |
| Widowed | 17 (21.5) | 11 (15.9) | 9 (12.2) | 37 (16.7) |
| Never Married | 5 (6.3) | 4 (5.8) | 12 (16.2) | 21 (9.5) |
| | | | | |
| Less than 7 yrs of school | 2 (2.5) | 1 (1.4) | 1 (1.4) | 4 (1.8) |
| Grades 7 through 9 | 5 (6.3) | 0 (0) | 0 (0) | 5 (2.3) |
| Grades 10 through 11 | 7 (8.9) | 4 (5.8) | 5 (6.8) | 16 (7.2) |
| High school graduate | 13 (16.5) | 16 (23.2) | 8 (10.8) | 37 (16.7) |
| 1 to 4 yrs of college | 13 (16.5) | 9 (13.0) | 22 (29.7) | 44 (19.8) |
| College graduate | 25 (31.6) | 21 (30.4) | 19 (25.7) | 65 (29.3) |
| Professional or Graduate school | 14 (17.7) | 18 (26.1) | 19 (25.7) | 51 (23.0) |
Yrs: years, OA: osteoarthritis, kg: kilograms, m: meters, %: validity percent.
Subject’s Medication at Baseline
| Oral hypoglycaemic agents | | | |
| Total | 2 (3) | 5 (7) | 9 (12) |
| Biguanide Class | 2 (3) | 4 (6) | 9 (12) |
| Sulfonylureas Class | 0 (0) | 0 (0) | 2 (3) |
| Thiazolidinedione | 0 (0) | 2 (3) | 2 (3) |
| Antihypertensive Agents | | | |
| Total | 22 (28) | 15 (22) | 15 (22) |
| Calcium channel blockers | 6(8) | 0(0) | 7(9) |
| Antiotensin-converting enzyme | 3 (4) | 7 (10) | 7 (9) |
| Angiotensin II receptor blockers | 6 (8) | 6 (9) | 3 (4) |
| Beta-blocker | 4 (5) | 3 (4) | 4 (5) |
| Alpha-blocker | 3 (4) | 0 (0) | 0 (0) |
| Diuretic | 5 (6) | 8 (12) | 5 (7) |
| Antiarrhythmic | 1 (1) | 0 (0) | 0 (0) |
| Anti-anginal | 1 (1) | 0 (0) | 0 (0) |
| Anti-platelet agent | 1 (1) | 1 (1) | 1 (1) |
| Anticoagulant | 0 (0) | 2 (3) | 0 (0) |
| Phosphodiesterase type 5 inhibitors | 0 (0) | 1 (1) | 0 (0) |
| Statins | 8 (10) | 12 (17) | 10 (14) |
| Hormone | | | |
| Total | 11 (14) | 10 (14) | 11 (15) |
| Thyroid | 5 (6) | 5 (7) | 8 (11) |
| Insulin | 0 (0) | 3 (4) | 1 (1) |
| Corticosteroid | 4 (5) | 2 (3) | 3 (4) |
| Progesterone | 1 (1) | 0 (0) | 1 (1) |
| Androgen | 1 (1) | 0 (0) | 0 (0) |
| Oestrogen | 1 (1) | 0 (0) | 0 (0) |
| Antithyroid | 0 (0) | 1 (1) | 0(0) |
| SERMs (Selective estrogen receptor modifiers) | 1 (1) | 0 (0) | 0 (0) |
| Beta 2-adrenergic receptor agonist (bronchodilator) | 2(3) | 1 (1) | 3 (4) |
| NSAIDs (Non-steroid anti-inflammatory drugs) | 26 (33) | 21 (30) | 18 (24) |
| COX-2 selective inhibitor | 3 (4) | 4 (6) | 1 (1) |
| NSAIDS | | | |
| Betahistine | 0 (0) | 1 (1) | 0 (0) |
| DMARDs (Disease modifying antirheumatic drugs) | 0 (0) | 1 (1) | 0 (0) |
| Histamine antagonist | 0 (0) | 2 (3) | 0 (0) |
| Bisphosphonate | 6 (8) | 4 (6) | 4 (5) |
| Antibiotics | 2 (3) | 1 (1) | 4 (5) |
| Analgesics | 1 (1) | 1 (1) | 3 (4) |
| Opiates | 0 (0) | 0 (0) | 2 (3) |
| Hypnotic | 4 (5) | 3 (4) | 4 (5) |
| Antidepressant | 7 (9) | 5 (7) | 7 (9) |
| Psychostimulant | 0 (0) | 1 (1) | 0 (0) |
| Antipsychotic | 0 (0) | 1 (1) | 0 (0) |
| Anti-manic | 0 (0) | 1 (1) | 0 (0) |
| Anti-convulsant | 1 (1) | 1 (1) | 0 (0) |
| Protein pump inhibitor (PPI) | 9 (11) | 5 (6) | 6 (8) |
| Enzyme inhibitor | 0 (0) | 1 (1) | 2 (3) |
| Muscle relaxant | 0 (0) | 1 (1) | 1 (1) |
| Antispasmodic | 0 (0) | 1 (1) | 0 (0) |
| Anti-cholinergic | 1 (1) | 1 (1) | 0 (0) |
| Antineoplastic | 2 (3) | 1 (1) | 0 (0) |
| Antimetabolite | 1 (1) | 1 (1) | 1 (1) |
| Antifolate | 0 (0) | 1 (1) | 1 (1) |
| Latanoprost | 0 (0) | 1 (1) | 0 (0) |
| Viscosupplementation | 0 (0) | 1 (1) | 0 (0) |
| Xanthine | 1 (1) | 0 (0) | 0 (0) |
| Antifungals | 0 (0) | 0 (0) | 1 (1) |
| Antimalarial | 0 (0) | 1 (1) | 1 (1) |
| Nitrate | 0 (0) | 0 (0) | 2 (3) |
| Laxative | 0 (0) | 0 (0) | 2 (3) |
| Supplements | 22 (28) | 22 (28) | 18 (24) |
| Homeopathic Medication | 1 (1) | 1 (1) | 1 (1) |
| None | 11 (14) | 10 (13) | 9 (12) |
| Not Specific | 21 (27) | 21 (27) | 20 (27) |
| Missing Data | | | |
| Total | 4 (5) | 8 (10) | 17 (23) |
| No Evaluation* | 2 (3) | 4 (5) | 7 (9) |
| No File** | 2 (3) | 4 (6) | 10 (14) |
This table presents a list of medications which participants declared to be taking at baseline. Data is presented as n (%).
Summary of adherence based on attendance marked in trainers’ manuals and individual walkers’ logbooks
| 0-3 months | 79 | 69 | 73 | *(0.043) | *(0.012) | (0.514) |
| | 0.770±0.299 | 0.802±0.290 | 0.652±0.403 | | | |
| 3-6 months | 79 | 69 | 73 | (0.242) | (0.159) | (0.774) |
| | 0.617±0.410 | 0.636±0.390 | 0.535±0.459 | | | |
| 6-9 months | 79 | 69 | 73 | (0.421) | (0.937) | (0.363) |
| | 0.471±0.418 | 0.534±0.425 | 0.528±0.463 | | | |
| 9-12 months | 79 | 69 | 73 | (0.549) | (0.551) | (0.989) |
| | 0.446±0.441 | 0.445±0.433 | 0.490±0.462 | | | |
| Total Adherence | 79 | 69 | 73 | (0.690) | (0.413) | (0.619) |
| 0.576±0.346 | 0.604±0.342 | 0.551±0.420 |
Summary of self-efficacy, measured with Stanford questionnaire on chronic disease for three study arms (continued)
| | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| | |||||||||
| Variables | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD |
| | | | | W.Vs. C(P) | W.Vs. C(P) | W.Vs. W(P) | W.Vs. C(P) | W.Vs. C(P) | W.Vs. W(P) |
| Coping | 79 | 69 | 73 | 44 | 44 | 40 | 44 | 41 | 36 |
| With | 1.069±794 | 1.126±0.775 | 1.013±0.946 | 0.864±0.771 | 1.239±0.730 | 1.192±0.835 | 1.064±0.952 | 1.388±0.856 | 1.342±1.127 |
| Symptoms | | | | (0.091) | (0.858) | (0.057) | (0.190) | (0.793) | (0.286) |
| Confidence | 79 | 69 | 73 | 44 | 44 | 39 | 43 | 41 | 36 |
| About | 7.406±1.719 | 7.827±1.488 | 7.858±1.512 | 7.826±1.551 | 7.682±1.785 | 8.064±1.575 | 7.690±1.920 | 7.546±1.848 | 8.015±1.476 |
| Doing Things | (0.433) | (0.297) | (0.060) | (0.235) | (0.422) | *(0.041) | |||
(Higher is better) W: Walking only group; WB: Walking and Behavioural Group; C: Self-directed group (unsupervised/self-directed); N: number of subjects in each comparative group; SD: standard deviation; vs: versus; data is presented as mean (standard deviation); p: p-value (statistical significance); * Statistically significant.
Figure 2Study flow diagram. This figure provides a flow diagram of data collection from baseline to 18-months follow-up.